We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
The latest trading session saw Amgen (AMGN - Free Report) ending at $314.90, denoting a -1.49% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily loss of 0.92%. On the other hand, the Dow registered a loss of 0.96%, and the technology-centric Nasdaq decreased by 1.6%.
Heading into today, shares of the world's largest biotech drugmaker had lost 3.4% over the past month, outpacing the Medical sector's loss of 4.16% and lagging the S&P 500's gain of 2.68% in that time.
Market participants will be closely following the financial results of Amgen in its upcoming release. The company plans to announce its earnings on October 30, 2024. In that report, analysts expect Amgen to post earnings of $5.11 per share. This would mark year-over-year growth of 3.02%. At the same time, our most recent consensus estimate is projecting a revenue of $8.51 billion, reflecting a 23.32% rise from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $19.48 per share and revenue of $33.22 billion. These totals would mark changes of +4.45% and +17.85%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.02% lower within the past month. At present, Amgen boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Amgen is presently being traded at a Forward P/E ratio of 16.41. This denotes a discount relative to the industry's average Forward P/E of 22.73.
One should further note that AMGN currently holds a PEG ratio of 2.84. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 2.37 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 76, finds itself in the top 31% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
The latest trading session saw Amgen (AMGN - Free Report) ending at $314.90, denoting a -1.49% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily loss of 0.92%. On the other hand, the Dow registered a loss of 0.96%, and the technology-centric Nasdaq decreased by 1.6%.
Heading into today, shares of the world's largest biotech drugmaker had lost 3.4% over the past month, outpacing the Medical sector's loss of 4.16% and lagging the S&P 500's gain of 2.68% in that time.
Market participants will be closely following the financial results of Amgen in its upcoming release. The company plans to announce its earnings on October 30, 2024. In that report, analysts expect Amgen to post earnings of $5.11 per share. This would mark year-over-year growth of 3.02%. At the same time, our most recent consensus estimate is projecting a revenue of $8.51 billion, reflecting a 23.32% rise from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $19.48 per share and revenue of $33.22 billion. These totals would mark changes of +4.45% and +17.85%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.02% lower within the past month. At present, Amgen boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Amgen is presently being traded at a Forward P/E ratio of 16.41. This denotes a discount relative to the industry's average Forward P/E of 22.73.
One should further note that AMGN currently holds a PEG ratio of 2.84. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 2.37 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 76, finds itself in the top 31% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.